Theravance Biopharma
TBPH
TBPH
86 hedge funds and large institutions have $1.08B invested in Theravance Biopharma in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
6% less capital invested
Capital invested by funds: $1.16B → $1.08B (-$72.2M)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
86
Holding in Top 10
1
Calls
$2.21M
Puts
$537K
Top Buyers
| 1 | +$26.8M | |
| 2 | +$7.14M | |
| 3 | +$3.8M | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.89M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.47M |
Top Sellers
| 1 | -$13.7M | |
| 2 | -$8.45M | |
| 3 | -$5.62M | |
| 4 |
LCM
Laurion Capital Management
New York
|
-$4.99M |
| 5 |
SAM
Senzar Asset Management
New York
|
-$3.64M |